Skip to main content

The Globe and Mail

Buyers eye multibillion-dollar deal for Brazilian drug maker

CEO of French drug maker Sanofi, Christopher Viehbacher, poses in Paris Feb. 7, 2013 after the French drug maker reported its net profit was more than halved in the fourth quarter from a year earlier. In 2009, Sanofi bought Brazilian generic drug maker Medley.

Jacques Brinon/AP

International drug companies are considering bidding for Ache Laboratorios Farmaceuticos, one of Brazil's biggest drug makers, in a deal valuing it at several billion dollars, according to people involved in the process.

Buying privately owned Ache could appeal to a number of drug firms looking to increase their footprint in Latin America – a region firmly on the radar screen of pharmaceutical groups hunting new markets as sales in Western countries sputter.

Sources said the Brazilian arm of investment bank Lazard LLC had been mandated by key shareholders to investigate a sale of Ache – and several European and U.S. drug makers had shown interest.

Story continues below advertisement

Whether a sale will be concluded is unclear, however, given divisions among the three family groups that control the company, with two more willing to sell than the third.

Ache's future was put further in the balance by the resignation on Wednesday of CEO Jose Ricardo Mendes da Silva. A company spokesman said he was leaving for personal reasons and an acting managing committee would now run the company.

The Ache spokesman declined to comment on whether the group would be sold, while officials at Lazard in London said they could not comment on the bank's role in the process.

Ache is a valuable prize in a fast-growing market and its sale would build on a number of deals in the Brazilian sector in recent years, including Sanofi's purchase of generic drug maker Medley for €500-million ($670-million U.S.) in 2009.

Sanofi paid 3.3 times historic sales for Medley. A similar multiple for Ache, which has sales of around $750-million a year, would give a price of $2.5-billion.

In practice, Ache's owners will be hoping for a lot more than that, reflecting Ache's much lower reliance on generic drugs, where margins have been seriously squeezed, and the higher demand for Latin American assets today than four years ago.

It was not clear which companies were looking at Ache but big emerging markets such as Brazil are a major focus for many leading pharmaceutical players, such as Pfizer Inc., GlaxoSmithKline PLC and Novartis AG.

Story continues below advertisement

Although it ranks fourth in terms of overall Brazilian drugs sales, Ache is the market leader in prescription medicines and has a track record of producing its own branded products.

In 2005, it developed the anti-inflammatory drug Acheflan from a native plant – the first medicine to be researched and developed entirely in Brazil.

It is also active in the fast-growing over-the-counter (OTC) health-care market.

Ache's exposure to cut-price generics is relatively limited, according to a report last month by Fitch Ratings, which forecast that its generic drug portfolio would not account for more than 10 to 15 per cent of future revenue.

Fitch said Ache's business position was "strengthening" and its profit margins were "strong and stable."

Revenue in the 12 months to Sept. 30. 2012 was 1.5-billion reais ($750-million), generating earnings before interest, tax, depreciation and amortization (EBITDA) of 540 million, Fitch said.

Story continues below advertisement

Ache has a staff of 3,300, including more than 1,600 sales representatives, and it has also been expanding overseas, with contracts to export 40 drugs to 12 different countries.

Report an error

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

Please note that our commenting partner Civil Comments is closing down. As such we will be implementing a new commenting partner in the coming weeks. As of December 20th, 2017 we will be shutting down commenting on all article pages across our site while we do the maintenance and updates. We understand that commenting is important to our audience and hope to have a technical solution in place January 2018.

Discussion loading… ✨